Abstract
Introduction: Human amniotic fluid (hAF) has been shown to reduce inflammation in multiple experimental models. hAF has previously been approved by the US Food and Drug Administration (FDA) as a human cellular and tissue product for tissue injury for human administration, and used safely in thousands of patients as a therapeutic treatment for diverse conditions. Given the profound inflammatory response observed in patients with COVID-19, and the successful completion of 10-patient pilot study of intravenous hAF, we present a trial design for a larger clinical trial of intravenous hAF for the treatment of COVID-19.
Methods and analysis: This paper describes the methodology of a phase I/II randomised, double-blinded, placebo-controlled clinical trial to determine the safety and feasibility of using acellular sterile filtered amniotic fluid as a treatment for patients with COVID-19. Primary outcome will be the change in C-reactive protein. Secondary outcomes include safety, biomarker inflammatory levels and clinically relevant outcomes at 30 days, including mortality, ventilator-free days and hospital and intensive care unit length of stay. Exploratory outcomes of health-related quality-of-life patient-reported outcomes will be collected. Hospitalised patients with laboratory-confirmed COVID-19 will be recruited.
Ethics and dissemination: This study was approved by the University of Utah Institutional Review Board (IRB_0013292), approved by the US FDA under Investigational New Drug (No 23369) and is registered on ClinicalTrials.gov. Results will be disseminated via peer-reviewed publications and conference presentations.
Trial registration number: NCT04497389 ; Pre-results.
Keywords: COVID-19; clinical trials; intensive & critical care; respiratory medicine (see thoracic medicine).
【저자키워드】 COVID-19, Critical care, clinical trials, respiratory medicine (see thoracic medicine), intensive &, 【초록키워드】 Treatment, Inflammation, clinical trial, Biomarker, Critical care, Mortality, Trial, randomised, intensive care, feasibility, hospital, Human, Ethics, clinical trials, C-reactive protein, drug, outcome, FDA, Patient, Amniotic fluid, Ventilator-free days, Hospitalised patients, Placebo, methodology, respiratory, university, Utah, Intensive, Critical, cellular, food, Inflammatory response, administration, Inflammatory, Thoracic, intravenous, tissue injury, life, registration number, institutional review board, US Food and Drug Administration, Primary outcome, tissue, Laboratory-confirmed COVID-19, Secondary outcomes, pilot study, double-blinded, Registered, placebo-controlled clinical trial, Drug administration, US FDA, laboratory-confirmed, experimental models, Therapeutic treatment, secondary, Result, shown, collected, include, recruited, clinically, approved, determine, reduce, conditions, New, peer-reviewed, amniotic, filtered, patients with COVID-19, ventilator-free day, 【제목키워드】 Treatment, protocol, randomised, Safety, feasibility, Patient, Amniotic fluid, placebo-controlled clinical trial, amniotic, filtered,